1. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22:433–443. PMID:
17555947.
2. Mizrahi R, Mamo D, Rusjan P, Graff A, Houle S, Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol 2009;12:715–721. PMID:
19366489.
3. Park KM, Ku J, Park IH, Park JY, Kim SI, Kim JJ. Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality. Hum Psychopharmacol 2009;24:619–627. PMID:
19946937.
4. Liberman RP, Mueser KT, Wallace CJ, Jacobs HE, Eckman T, Massel HK. Training skills in the psychiatrically disabled: learning coping and competence. Schizophr Bull 1986;12:631–647. PMID:
3810067.
5. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007;68:29–36. PMID:
17284127.
6. Livingston MG. Risperidone. Lancet 1994;343:457–460. PMID:
7508541.
7. Vinkers CH, Mirza NR, Olivier B, Kahn RS. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Expert Opin Investig Drugs 2010;19:1217–1233.
8. Choe BY, Kim KT, Suh TS, Lee C, Paik IH, Bahk YW, et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol 1994;1:211–216. PMID:
9419488.
9. Tayoshi S, Nakataki M, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2010;117:83–91. PMID:
20022731.
10. Adolphs R. The social brain: neural basis of social knowledge. Annu Rev Psychol 2009;60:693–716. PMID:
18771388.
11. Frith CD. The social brain? Philos Trans R Soc Lond B Biol Sci 2007;362:671–678. PMID:
17255010.
12. Gallese V. Before and below 'theory of mind': embodied simulation and the neural correlates of social cognition. Philos Trans R Soc Lond B Biol Sci 2007;362:659–669. PMID:
17301027.
13. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. 1996,New York: New York State Psychiatric Institute Biometric Research.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276. PMID:
3616518.
15. Lee JD, Park HJ, Park ES, Kim DG, Rha DW, Kim EY, et al. Assessment of regional GABA(A) receptor binding using 18F-fluoroflumazenil positron emission tomography in spastic type cerebral palsy. Neuroimage 2007;34:19–25. PMID:
17049274.
16. Millet P, Graf C, Buck A, Walder B, Ibanez V. Evaluation of the reference tissue models for PET and SPECT benzodiazepine binding parameters. Neuroimage 2002;17:928–942. PMID:
12377167.
17. Nichols T, Hayasaka S. Controlling the familywise error rate in functional neuroimaging: a comparative review. Stat Methods Med Res 2003;12:419–446. PMID:
14599004.
18. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 2008;13:663–681. PMID:
18704022.
19. Olson IR, Plotzker A, Ezzyat Y. The Enigmatic temporal pole: a review of findings on social and emotional processing. Brain 2007;130:1718–1731. PMID:
17392317.
20. Constantinidis C, Williams GV, Goldman-Rakic PS. A role for inhibition in shaping the temporal flow of information in prefrontal cortex. Nat Neurosci 2002;5:175–180. PMID:
11802172.
21. Van Overwalle F. Social cognition and the brain: a meta-analysis. Hum Brain Mapp 2009;30:829–858. PMID:
18381770.
22. Daw ND, O'Doherty JP, Dayan P, Seymour B, Dolan RJ. Cortical substrates for exploratory decisions in humans. Nature 2006;441:876–879. PMID:
16778890.
23. Weissman DH, Perkins AS, Woldorff MG. Cognitive control in social situations: a role for the dorsolateral prefrontal cortex. Neuroimage 2008;40:955–962. PMID:
18234518.
24. Chai XJ, Whitfield-Gabrieli S, Shinn AK, Gabrieli JD, Nieto Castanon A, McCarthy JM, et al. Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia. Neuropsychopharmacology 2011;36:2009–2017. PMID:
21654735.
25. Pomarol-Clotet E, Canales-Rodriguez EJ, Salvador R, Sarro S, Gomar JJ, Vila F, et al. Medial prefrontal cortex pathology in schizophrenia as revealed by convergent findings from multimodal imaging. Mol Psychiatry 2010;15:823–830. PMID:
20065955.
26. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, et al. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2012;69:449–459. PMID:
22213769.
27. Maldonado-Aviles JG, Curley AA, Hashimoto T, Morrow AL, Ramsey AJ, O'Donnell P, et al. Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2009;166:450–459. PMID:
19289452.
28. Sawaguchi T, Yamane I, Kubota K. Application of the GABA antagonist bicuculline to the premotor cortex reduces the ability to withhold reaching movements by well-trained monkeys in visually guided reaching task. J Neurophysiol 1996;75:2150–2156. PMID:
8734611.
29. Yu H, Sternad D, Corcos DM, Vaillancourt DE. Role of hyperactive cerebellum and motor cortex in Parkinson's disease. Neuroimage 2007;35:222–233. PMID:
17223579.
30. Peters S, Suchan B, Rusin J, Daum I, Koster O, Przuntek H, et al. Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients. Neuroreport 2003;14:809–812. PMID:
12858037.
31. Bozikas VP, Kosmidis MH, Kafantari A, Gamvrula K, Vasiliadou E, Petrikis P, et al. Community dysfunction in schizophrenia: rate-limiting factors. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:463–470. PMID:
16442195.